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Abstract
 
Polymorphonuclear leukocytes (PMNs) characterize the pathology of T cell–mediated autoim-
mune diseases and delayed-type hypersensitivity reactions (DTHRs) in the skin, joints, and gut,
but are absent in T cell–mediated autoimmune diseases of the brain or pancreas. All of these re-
 
actions are mediated by interferon
 
 
 
g
 
–producing type 1 T cells and produce a similar pattern of
cytokines. Thus, the cells and mediators responsible for the PMN recruitment into skin, joints,
or gut during DTHRs remain unknown. Analyzing hapten-induced DTHRs of the skin, we
found that mast cells determine the T cell–dependent PMN recruitment through two mediators,
tumor necrosis factor (TNF) and the CXC chemokine macrophage inflammatory protein 2
(MIP-2), the functional analogue of human interleukin 8. Extractable MIP-2 protein was abun-
dant during DTHRs in and around mast cells of wild-type (WT) mice but absent in mast cell–
 
deficient WBB6F
 
1
 
-
 
Kit
 
W
 
/
 
Kit
 
W-
 
v 
 
(
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
) mice. T cell–dependent PMN recruitment was re-
duced 
 
.
 
60% by anti–MIP-2 antibodies and 
 
.
 
80% in mast cell–deficient 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 mice. Mast
cells from WT mice efficiently restored DTHRs and MIP-2–dependent PMN recruitment in
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 mice, whereas mast cells from TNF
 
2
 
/
 
2
 
 mice did not. Thus, mast cell–derived TNF
and MIP-2 ultimately determine the pattern of infiltrating cells during T cell–mediated DTHRs.
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Introduction
 
Recruitment of polymorphonuclear leukocytes (PMNs)
into sites of inflammation plays a central role in the patho-
genesis of rheumatoid arthritis, Crohn’s disease, inflamma-
tory bowel disease, or psoriasis, whereas PMNs are virtually
absent during other T cell–mediated diseases such as exper-
 
imental allergic encephalomyelitis (EAE)
 
1
 
 or autoimmune
pancreatitis (1–11). All of these diseases are considered to
be the consequence of delayed-type hypersensitivity reac-
tions (DTHRs), which are induced by IFN-
 
g
 
–producing
type 1 T cells. The data suggest not only that PMN recruit-
ment is determined by the functional phenotype of the in-
filtrating T cells, but also that resident cells control PMN
recruitment into the skin, joints, or gut when activated by
infiltrating type 1 T cells.
Recruitment of PMNs into sites of inflammation re-
quires two major events, attachment and migration (12,
13). TNF and IL-1 induce the expression of adhesion mol-
ecules such as intercellular adhesion molecule 1 (ICAM-1)
and vascular cell adhesion molecule 1 (VCAM-1) on en-
dothelial cells, which are required for the attachment of
lymphocytes and of PMNs (14). However, TNF induction
alone is not sufficient for PMN recruitment. Thus, PMNs
 
Address correspondence to Martin Röcken, Department of Dermatology
and Allergology, Ludwig-Maximilians-University Munich, Frauenlobstr.
9-11, 80337 Munich, Germany. Phone: 49-89-5160-6205; Fax: 49-89-
5160-6206; E-mail: martin.roecken@lrz.uni-muenchen.de
 
1
 
Abbreviations used in this paper:
 
 BMMC, bone marrow–derived mast
cell; CHSR, contact hypersensitivity reaction; DTHR, delayed-type hy-
persensitivity reaction; EAE, experimental allergic encephalomyelitis; IP,
IFN-
 
g
 
 inducible protein; KC, cytokine-induced neutrophil chemoattrac-
tant; MIP, macrophage inflammatory protein; MPO, myeloperoxidase;
TNCB, trinitrochlorobenzene; WT,
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are absent during T cell–mediated destruction of islet cells
in nonobese diabetes or EAE, two strictly TNF-dependent
DTHRs (10, 15). T cell–mediated PMN recruitment into
sites of inflammation therefore requires chemoattractants in
addition to TNF.
In the mouse, the two best-defined chemokines capable
of recruiting PMNs are cytokine-induced neutrophil
chemoattractant (KC), the homologue of the human chemo-
kine growth-related oncogene (GRO) (16), and macro-
phage inflammatory protein (MIP)-2, considered as the
functional analogue of human IL-8 (17). Both CXC
chemokines can be produced by a variety of hematopoi-
etic, epithelial, and stromal cells, and bind to the chemokine
receptor CXCR2. Studying PMN recruitment into the
skin during T cell–independent, toxic reactions, Fairchild
and coworkers found that a chemokine derived from kera-
tinocytes, the CXC chemokine KC, is capable of recruiting
PMNs into the epidermis (18).
Although innate and toxic reactions can induce the pro-
duction of TNF and chemokines by numerous cells, in-
cluding epithelia, endothelia, and stromal cells, the relative
contribution of these different cell types to the organization
of a strictly T cell–mediated inflammation remains unclear
(19). An emerging concept suggests that hematopoietic
cells provide the TNF required for T cell–mediated
DTHRs (19), even though the cellular source providing
this TNF remains open. T cells and macrophages are both
needed for the appropriate development of DTHRs and
are considered an important source of TNF (20, 21). How-
ever, B cell–deficient or mast cell–deficient mice also have
profound defects in various DTHRs, suggesting an impor-
tant role for B cell– and mast cell–derived mediators during
the organization of DTHRs (22–24).
Mast cells are capable of producing large amounts of
TNF (25) and chemokines, including MIP-2/IL-8 (26–28),
and have been shown to provide the biologically relevant
TNF during innate (29, 30) and IgE-mediated (31) immune
reactions. Moreover, mast cells can enhance T cell–depen-
dent DTHRs, such as EAE (32) and contact hypersensitiv-
ity reactions (CHSRs; reference 23), which are attenuated
in mast cell–deficient WBB6F
 
1
 
-
 
Kit
 
W
 
/
 
Kit
 
W
 
-v 
 
(
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
)
mice. More detailed analysis of CHSRs in mast cell–defi-
cient 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 
 
mice revealed that hapten-specific
DTHRs seem to have a normal T cell infiltrate (33, 34) but
are almost devoid of PMNs (24). As mast cells are an impor-
tant source of cytokines and chemokines, including TNF
and MIP-2/IL-8 (29, 30), they may provide the central me-
diators recruiting PMNs during T cell–dependent DTHRs.
To analyze the mechanisms responsible for PMN re-
cruitment during type 1 T cell responses, we used trinitro-
chlorobenzene (TNCB)-induced CHSRs. TNCB-induced
DTHRs are strictly dependent on hapten-specific, type 1
memory T cells and are associated with a strong infiltrate of
PMNs. These memory T cells lead to CHSRs when the
hapten is applied to the skin of sensitized mice (34) and
to inflammatory bowel disease, an important model of
Crohn’s disease, when the hapten is applied intrarectally
(35). Using TNCB-induced CHSRs as a model disease, we
 
found that mast cells are the central hematopoietic cells
regulating PMN recruitment in response to infiltrating type
1 T cells by delivering both the TNF and the MIP-2 re-
quired for the migration of PMNs.
 
Materials and Methods
 
Animals.
 
Female BALB/c or C57BL/6 mice were from
Charles River Laboratories; TNF
 
2
 
/
 
2
 
 129/Svx C57BL/6 mice
(36) and TNF
 
1
 
/
 
1
 
 129/Svx C57BL/6 mice, genetically mast cell–
deficient 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 mice, and congenic normal WBB6F
 
1
 
1
 
/
 
1
 
(
 
Kit
 
1
 
/
 
1
 
) mice were bred at the GSF-National Research Center.
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 mice are derived from heterozygous breeder pairs
originally obtained from The Jackson Laboratory. Adult 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 mice contain 
 
,
 
1.0% of the number of dermal mast cells
present in the skin of the congenic wild-type (WT) mice. All
mice were between 6 and 10 wk of age.
 
Reagents and Abs.
 
TNCB was a gift from Dr. S. Katz (Na-
tional Institutes of Health, Bethesda, MD), anti-Thy 1.2 mAb
(T23) was a gift from Dr. R. Mocikat (GSF, Munich, Germany),
recombinant mouse IL-1
 
b
 
 and MIP-2 were from R&D Systems,
IL-2 was from Chiron Corp., and ionomycin was from Sigma-
Aldrich. Anti–MIP-2 serum was as described (37).
 
In Vivo Experiments.
 
BALB/c mice were sensitized with 7%
TNCB (100 
 
m
 
l of a 4:1 mixture of acetone/olive oil) at the
shaved abdomen. As in pilot studies, the majority of 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
mice died when we used this strong sensitization protocol; sensi-
tizations in experiments that involved 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 
 
and congenic
WT mice were carried out with 2% TNCB (20 
 
m
 
l of a 4:1 mix-
ture of acetone/olive oil) at both sides of one ear. This protocol
induced similar ear swelling responses after elicitation in WT
mice without causing mortality in 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 
 
mice after sensiti-
zation. 1 wk later, mice were challenged with 1% TNCB (20 
 
m
 
l
of a 1:9 mixture of acetone/olive oil) on both sides of the previ-
ously untreated ear. Where indicated,
 
 Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 
 
and congenic
WT mice were sensitized on both sides of one ear with 1.6% ox-
azolone (20 
 
m
 
l of a 4:1 mixture of acetone/olive oil) and, 1 wk
later, challenged with 0.8% oxazolone (20 
 
m
 
l of a 1:9 mixture of
acetone/olive oil). Specific ear swelling was determined by mea-
suring ear thickness with a micrometer (Oditest
 
®
 
; Kroeplin) be-
fore and 24 h after TNCB challenge (34). Nonspecific swelling,
caused by 1% TNCB in five naive animals (irritant reaction), was
subtracted. Anti–MIP-2 (30 
 
m
 
l) or preimmune serum was in-
jected intracutaneously 1.5 h before the TNCB challenge. 
 
Kit
 
W
 
/
 
Kit
 
W
 
-v
 
 
 
mice were locally reconstituted with mast cells by inject-
ing intracutaneously 0.5 
 
3
 
 10
 
6
 
 cultured bone marrow–derived
mast cells (BMMCs) 5 wk before the sensitization, exclusively
into the ear selected for the elicitation of CSHRs.
 
Histology and Immunohistology.
 
Ear tissue was collected 24 h
after TNCB challenge and sections were stained with hematoxy-
lin and eosin. For immunoperoxidase staining, formalin-fixed and
paraffin-embedded sections were dewaxed and rehydrated
through graded concentrations of ethanol. Alternatively, we used
frozen tissue. The thawed tissues were fixed with acetone. Tissue
sections were incubated with either anti–MIP-2 antiserum (37)
or preimmune serum, washed, incubated for 10 min in secondary
goat anti–rabbit serum, washed, and incubated with peroxidase–
antiperoxidase complex (Dako). After development, sections
were counterstained with alcian blue.
 
Protein Analysis.
 
Protein was extracted from ear tissues and
MIP-2 was determined by using rat anti–mouse MIP-2 mAb
(MAB452; R&D Systems) for coating and anti–MIP-2 serum 
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(37) for detection, followed by horseradish peroxidase–conju-
gated goat anti–rabbit Ig and 2,2
 
9
 
-azinobis(3-ethylbenzthiazo-
linesulfonic acid) (ABTS; Boehringer Mannheim) as substrate
(BD PharMingen).
 
 
 
Myeloperoxidase (MPO) activity was deter-
mined in protein extracts from frozen ear tissue and MPO activ-
ity was expressed as units per gram (37). MPO activity of sensi-
tized WT mice samples was set as 100%.
 
PCR.
 
Mouse ears were directly frozen in liquid nitrogen
24 h after the TNCB challenge and homogenized in lysis buffer
without thawing. Total RNA was purified (RNeasy kit;
QIAGEN), reverse transcribed into cDNA, and analyzed by
PCR as described (38). Equal amounts of RNA from individual
mice were reverse transcribed into cDNA. 20 ng of cDNA was
amplified with intron-spanning primer pairs for 25 cycles (1
 
 
 
min
at 95
 
8
 
, 1 min at 65
 
8
 
, 1 min at 72
 
8
 
, 5 min at 72
 
8
 
C final) in 25 
 
m
 
l
with oil overlay. Equal volumes of cDNAs were amplified by
PCR. 10 
 
m
 
l of amplificates was visualized by ethidium bromide
staining after agarose gel electrophoresis and quantified with an
electronic video system and analysis software (WinCam 2.1; Cy-
bertec). The following primers were used (the sequences are
given in the 59 to 39 direction): KC (530-bp amplificate), 59-
AACGGAGAAAGAAGACAGACTGCT and 39-GACGAGA-
CCAGGAGAAACAGGG; IFN-g inducible protein of 10 kD
(IP-10; 256 bp), 59-TCCCTCTCGCAAGGACGGTC and 39-
GTGTGTGCGTGGCTTCACTC; MIP-1a (275 bp), 59-CCT-
GCTCAACATCATGAAGGTCTC and 39-GGTCAGTGAT-
GTATTCTTGGACC; MIP-1b (540 bp), 59-CCACAATAG-
CAGAGAAACAGCAAT and 39-AACCCCGAGCAACACC-
ATGAAG; MIP-2 (466 bp), 59-AGTTTGCCTTGACCCT-
GAAGCC and 39-TGGGTGGGATGTAGCTAGTTCC; TNF
(353 bp), 59-CTCTTCTGTCTACTGAACTTCGG and 39-
AGATAGCAAATCGGCTGACGG; monocyte chemoattrac-
tant protein 1 (345 bp), 59-ACCTGCTGCTACTCATTCACC
and 39-CACTGTCACACTGGTCACTCC; glyceraldehyde
3-phosphate dehydrogenase (GAPDH; 669 bp), 59-CTCACT-
CAAGATTGTCAGCAATG and 39-GAGGGAGATGCTCA-
GTGTTGG; and aldolase (571 bp), 59-AGCTGTCTGACA-
TCGCTCACCG and 39-CACATACTGGCAGCGCT-
TCAAG.
Cell Cultures. T cells were isolated from draining lymph
nodes and 125 3 103 or 250 3 103 T cells were stimulated with
either unmodified or hapten-modified T cell–depleted spleen
cells (5 3 105) in a total volume of 250 ml of medium. After 72 h
of culture in DMEM containing 10% FCS, 2-mercaptoethanol,
and 2 mM glutamine (all from Biochrom) at 378C in a humidi-
fied atmosphere with 5% CO2, cells were pulsed with [3H]thymi-
dine for the final 6–8 h. Femoral Kit1/1 bone marrow cells were
cultured in the presence of IL-3 and c-kit ligand. After 4 wk of
culture, BMMCs were either used in vivo or stimulated in vitro
with ionomycin (2 mM) and recombinant mouse IL-1b (2 ng/
ml; reference 39). Cells were harvested for mRNA analysis and
supernatants for MIP-2 determination after 24 h.
Figure 1. Selective induction of
MIP-2 during T cell–dependent CHSRs.
TNCB-sensitized mice were challenged
with TNCB, 2 d after T cell depletion
with anti-Thy 1.2 mAb or sham treatment
(A). TNCB-sensitized (B)  or naive  (C)
mice were challenged with TNCB to
elicit either a CHSR (B) or an irritant re-
action (C). Ear sections were hematoxylin
and eosin–stained for microphotographs.
mRNA was extracted from ear tissue of
untreated mice (left lane), of naive mice
challenged for 24 h with TNCB (irritant
reaction, middle lane), or of sensitized
mice (CHSR, right lane) 24 h after chal-
lenge with TNCB (D). MIP-2 was deter-
mined by ELISA in protein extracts from
ear tissue (E) either from untreated mice
(top) or 24 h after challenging either naive
mice (irritant reaction, middle) or sensi-
tized mice with TNCB (CHSR, bottom).
Hapten treatment, protein and mRNA extractions, reverse transcription, amplifi-
cation, and evaluation were performed as described in Materials and Methods. DL,
detection limit; MCP-1, monocyte chemoattractant protein 1.1444 Mast Cells Control Neutrophil Recruitment in T Cell–mediated Reactions
Statistical Analysis. Differences of specific ear swelling (6 SD)
were determined using the two-tailed Student’s t test and consid-
ered significant at P , 0.05.
Results
Selective Induction of MIP-2 during T Cell–dependent
DTHRs. To analyze the mechanisms that control PMN
recruitment during T cell–mediated DTHRs, we selected
hapten-induced CHSRs, a strictly T cell–dependent type
of DTHR (Fig. 1 A) that is associated with strong PMN
recruitment (Fig. 1, B and C). Comparing the chemokine
mRNA expression pattern of T cell–dependent, hapten-
induced CHSRs (Fig. 1 B) with that of T cell–indepen-
dent, hapten-induced irritant reactions (Fig. 1 C), we found
two strikingly different profiles. Some CXC and CC
chemokines, such as KC or monocyte chemoattractant
protein 1, were already induced during T cell–indepen-
dent, TNCB-induced irritant reactions in nonsensitized
control mice (Fig. 1 D). In sharp contrast, others, such as
the CXC chemokines MIP-2 and IP-10 and the CC
chemokines MIP-1a and MIP-1b, were selectively in-
creased during the T cell–dependent DTHRs in sensitized
mice (Fig. 1 D). TNF was already induced in irritant reac-
tions, as described by others (40). However, the expression
increased during CHSRs (Fig. 1 D). MIP-1a, MIP-1b,
and IP-10 regulate T lymphocyte recruitment during
DTHRs and exhibit no chemotactic activity on PMNs (8,
41, 42). MIP-2 and KC bind to the chemokine receptor
CXCR2 and have important chemotactic activities on
mouse PMNs (18, 43). TNCB-induced irritant reactions in
nonsensitized control mice are almost devoid of PMNs
(Fig. 1 C) despite strong expression of KC mRNA (Fig. 1
D), whereas PMNs are prominent during T cell–depen-
dent DTHRs (Fig. 1 B). Thus, in WT mice, MIP-2
mRNA and not KC mRNA expression correlated with
TNCB-specific PMN recruitment during this adaptive im-
mune response. MIP-2 protein production closely corre-
lated with MIP-2 mRNA expression and was exclusively
increased in protein extracts of ear tissues undergoing hap-
ten-specific DTHRs (Fig. 1 E). Production of MIP-2 pro-
tein was strictly dependent on T cells, as T cell depletion
not only suppressed ear swelling but also PMN recruitment
and MIP-2 expression (Fig. 1 A and data not shown).
Figure 2. A critical role of MIP-2 for
PMN recruitment during CHSRs. TNCB-
sensitized mice were challenged with hap-
ten 1.5 h after intracutaneous injection of
either preimmune serum or anti–MIP-2 se-
rum (A). Representative microphotographs
of hematoxylin and eosin–stained CHSR
reactions in mice pretreated with preim-
mune serum (B) or anti–MIP-2 serum (C).
MPO activity in protein extracts from ear
tissues (D) challenged with TNCB after
pretreatment with either preimmune serum
or anti–MIP-2 serum1445 Biedermann et al.
Control of PMN Recruitment by MIP-2. To determine
whether MIP-2 production was of functional relevance for
the recruitment of PMNs, we neutralized MIP-2 with a
specific Ab at the site of TNCB application. Local injection
of anti–MIP-2 Ab reduced hapten-specific ear swelling by
z60% (Fig. 2 A). More importantly, it also reduced PMN
recruitment $60%, as determined by histology (Fig. 2, B
and C) and determination of MPO activity (Fig. 2 D).
MIP-2 Production by Mast Cells In Vivo and In Vitro.
Several cells have been suggested as putative source for the
cytokines regulating PMN attraction in DTHRs. In the
skin, keratinocytes, fibroblasts, endothelial cells, APCs, or
T lymphocytes (22, 44, 45) count among the most impor-
tant candidates. Surprisingly, immunohistology of ears un-
dergoing CHSRs revealed that MIP-2 reactivity localized
almost exclusively to mast cells, whereas keratinocytes and
endothelia showed only very weak immunoreactivity (Fig.
3 A). Especially during early phases of the CHSR, at 7 h, at
least 80% of mast cells were strongly MIP-2 positive (data
not shown). No MIP-2 protein was visible in fibroblasts
and keratinocytes and, only at 24 h, relatively little around
infiltrating PMNs. Although keratinocytes largely exceed
mast cells by number (Fig. 3 A), they are separated from
dermal vessels by space and a basal membrane, and the in-
fluence of keratinocyte-derived cytokines on the underly-
ing tissues is still not clear (46). Mast cells are abundant in
the dermal tissue (7,000/mm3) and in close proximity to
the small vessels that nurture the skin (Fig. 3 A).
Mast cells strongly increased MIP-2 mRNA expression
(Fig. 3 B) and produced large amounts of MIP-2 protein
when stimulated with ionomycin and IL-1 in vitro (39;
Fig. 3 C). As MIP-2 was also induced by coincubating mast
cells with IFN-g–producing type 1 T cells (data not
shown), mast cell–T cell interactions may also induce the
production of the MIP-2 protein required for PMN re-
cruitment in vivo.
Mast Cell–dependent PMN Recruitment during Hapten-spe-
cific DTHRs. Thus, keratinocytes and mast cells seem to
be the two potential sources capable of providing the MIP-2
required for PMN recruitment. To determine the role of
mast cells and mast cell–derived MIP-2 during T cell–
dependent PMN recruitment, we first analyzed TNCB-
induced CHSRs in mast cell–deficient KitW/KitW-v mice.
As reported by others (24), mast cell–deficient KitW/KitW-v
mice had 50–70% reduced tissue swelling compared with
WT mice (Fig. 4 A). Reduced ear swelling was associated
with severely impaired PMN recruitment during hapten-
specific CHSRs, as demonstrated by the strongly reduced
number of abscesses (#10%; Fig. 4, B and C) and the low
MPO activity (Fig. 4 E). Using oxazolone as an alternative
hapten, we also found 60% reduction of the ear swelling in
KitW/KitW-v mice (P 5 0.018), and the number of PMN
abscesses was again reduced to z10% in KitW/KitW-v mice.
Importantly, T cell responses were not impaired in KitW/
KitW-v mice. Hapten-specific T cell proliferation (Fig. 4 F)
and the precursor frequency of hapten-specific IFN-g–pro-
ducing T cells (not shown) was identical in KitW/KitW-v
and congenic WT mice. The mean number of small
mononuclear cells per 0.5-mm ear section was similar in
KitW/KitW-v and congenic WT mice (96 6 15 and 111 6
13 cells, respectively, mean 6 SEM, n 5 4; see also Fig. 4,
B and C), as reported previously (33, 34).
PMN Recruitment Requires Mast Cell–derived MIP-2.
Extractable MIP-2 protein was absent in mast cell–deficient
KitW/KitW-v mice during TNCB-induced CHSRs (Fig. 4
G). These data suggest that the biologically active MIP-2
required for PMN recruitment during T cell–dependent
CHSRs was dependent on the presence of mast cells and
that the T cell–dependent MIP-2 mRNA expression in ear
tissue of KitW/KitW-v  mice was of minor relevance for
PMN recruitment. To address this hypothesis, we reconsti-
tuted  KitW/KitW-v  mice with in vitro–cultured BMMCs
Figure 3. MIP-2 production by mast cells in vivo and in vitro. Mi-
crophotograph of an ear section stained for mast cells (A) with alcian
blue and with anti–MIP-2 serum using immunoperoxidase staining
(arrows). Controls using only primary or secondary Ab or preimmune
serum showed no significant staining. MIP-2 mRNA expression of
cultured mast cells (B) 24 h after stimulation with medium, ionomy-
cin, or ionomycin and IL-1. Reverse transcription PCR was carried
out with primers for MIP-2 mRNA (30 cycles). IL-1 alone did not
induce MIP-2 mRNA expression. MIP-2 content in the supernatants from mast cells stimulated for 24 h with ionomycin and IL-1 was determined by
ELISA (C). No or only very minor MIP-2 mRNA or MIP-2 protein was detected when mast cells were stimulated with either ionomycin or IL-1 alone.1446 Mast Cells Control Neutrophil Recruitment in T Cell–mediated Reactions
exclusively at the site selected for DTHR elicitation (29,
31). After local reconstitution with WT BMMCs, the ear
tissues again contained large amounts of extractable MIP-2
protein during CHSRs (Fig. 4 G). Similarly, hapten-spe-
cific ear swelling (Fig. 4 A), PMN recruitment (Fig. 4 D),
and MPO activity (Fig. 4 E) were restored. These effects of
mast cell reconstitution were again entirely antagonized by
anti–MIP-2 Ab (Fig. 4, A and E).
PMN Recruitment Requires Mast Cell–derived TNF. As
mast cell–derived TNF is needed for PMN recruitment
during innate (29, 30) and IgE-mediated immune responses
(47), and as TNF is also needed for the expression of adhe-
sion molecules involved in the induction of CHSRs (14),
we analyzed the role of mast cell–derived TNF in T cell–
dependent CHSRs. We locally reconstituted ears of mast
cell–deficient KitW/KitW-v  mice with BMMCs generated
from either TNF1/1 or TNF2/2 mice. As shown in Fig. 5
A, adoptively transferred BMMCs from TNF2/2 mice re-
stored neither ear swelling (Fig. 5 A) nor PMN recruitment
in KitW/KitW-v mice. In sharp contrast, BMMCs from WT
mice entirely restored CHSRs and PMN recruitment in
KitW/KitW-v mice (Fig. 5 A). The number of mast cells in
the ears of KitW/KitW-v mice reconstituted with mast cells
derived from WT mice was similar to that found in ears re-
constituted with mast cells from TNF2/2 mice (z16 mast
cells per 2-mm ear section). Thus, the reduced ear swelling
and PMN recruitment were directly related to the missing
TNF production by mast cells. During CHSRs, both
TNF2/2 and TNF1/1 mast cells stained strongly positive
for MIP-2 (Fig. 6, A–C), suggesting that MIP-2 produc-
tion by these mast cells was TNF independent. To analyze
MIP-2 production in a completely TNF-free environment,
we induced CHSRs in TNF2/2 mice and determined
MIP-2 reactivity in frozen ear sections. Again, strong MIP-2
Figure 4. Mast cell–derived MIP-2 is required for PMN recruitment dur-
ing CHSRs. Mast cell (MC)-deficient KitW/KitW-v mice, congenic WT mice,
or mast cell–reconstituted KitW/KitW-v mice were sensitized and challenged
with TNCB, 1.5 h after pretreatment with either anti–MIP-2 or preimmune
serum. Specific increase of ear thickness 24 h after the challenge (A). Micro-
photographs of hematoxylin and eosin–stained ear sections of CHSR reaction
in a WT (B), KitW/KitW-v (C), and mast cell–reconstituted KitW/KitW-v mouse
(D). MPO activity was determined in protein extracts from ear tissue of the
indicated four experimental groups (E). T cells from unsensitized WT or from
draining lymph nodes of sensitized KitW/KitW-v, congenic WT, or mast cell–
reconstituted KitW/KitW-v mice were stimulated for 72 h with either naive or
TNBS-modified APCs; [3H]thymidine was added for the final 6 h (F). MIP-2
protein in ear tissue was determined from the three experimental groups, 24 h
after the TNCB challenge (G). Asterisks indicate significant differences in ear
thickness between groups of animals (P , 0.05). DL, detection limit.1447 Biedermann et al.
reactivity was found and was almost entirely restricted to
mast cells (Fig. 6 D). Thus, mast cell–derived TNF is essen-
tial for T cell–mediated PMN recruitment during this
CHSR, even in the presence of the most potent neutro-
phil-attracting chemokines, such as MIP-2/IL-8. Even
though TNF and MIP-2 can be produced by a variety of
cells, and even though TNF mRNA and MIP-2 mRNA
expression increased in the ear tissue of TNCB-challenged
KitW/KitW-v mice (data not shown), the adoptive transfer
experiments clearly demonstrated that the TNF and MIP-2
relevant for PMN recruitment were dependent on the
presence of mast cells.
Discussion
These data demonstrated a novel, unexpected role for
hematopoietic cells by showing that tissue mast cells not
only are involved in the initiation and amplification of
DTHRs (27, 32), but also determine the pattern of cells in-
filtrating into sites of inflammation through the chemo-
kines they produce. Both TNF and MIP-2 were essential
for appropriate PMN recruitment during TNCB-induced
CHSRs, and both were dependent on the presence of mast
cells. The combination of these two mediators is of special
importance for PMN recruitment, as TNF and MIP-2 pro-
vide two qualitatively different but synergistic signals. The
major biological significance of TNF seems to be the in-
duction of adhesion molecules required for PMN attach-
ment to endothelial cells (14), whereas MIP-2 establishes a
chemotactic gradient required for diapedesis and directed
migration of PMNs (48–50). These data support the
emerging concept postulating that TNF of predominantly
hematopoietic origin regulates leukocyte movement (19).
More importantly, however, they showed that hematopoi-
etic cells may even provide the chemokines regulating
PMN recruitment into sites of inflammation. TNF was not
required for MIP-2 induction during CHSRs, as TNCB
application induced equivalent levels of MIP-2 in TNF2/2
and WT mice (Figs. 3 A and 6 D, and data not shown).
In vivo induction of MIP-2 during CHSRs was strictly
dependent on the presence of mast cells and on local acti-
vation of memory-type T cells (Fig. 1), which shows that
the infiltrating type 1 T cells deliver signals that induced
both TNF and MIP-2 production by mast cells. Our in
vivo data do not allow for the determination of whether T
cell–mast cell interactions can directly result in TNF and
MIP-2 production or whether intermediate cells, such as
APCs or fibroblasts, provided the signals required for mast
cell activation and MIP-2 production in vivo. Preliminary
in vitro data suggest that T cells can directly induce MIP-2
production by mast cells. Thus, culture of mast cells in the
presence of hapten-specific type 1 T cells resulted in signif-
icant MIP-2 production (Kneilling, M, T. Biedermann, L.
Hultner, and M. Rocken, unpublished data), suggesting
that T cell–mast cell interactions lead not only to mast cell
degranulation (51), but also to cytokine and chemokine
production (52).
Various groups that have examined CHSRs in normal
versus mast cell–deficient mice reported divergent results.
Some found equivalent ear swelling responses in mast cell–
deficient and WT mice (33, 34), whereas others found
strongly reduced ear swelling responses in mast cell–defi-
cient animals (23, 24). Similarly, in another T cell–depen-
dent inflammatory immune response, allergic asthma, mast
cells contributed to the tissue inflammation under some
but not all experimental conditions. These different re-
quirements for mast cells during T cell–mediated immune
responses suggest that the requirement for mast cells de-
pends on the strength of these immune responses. This
strength is influenced by various additional factors such as
concentration of the allergen/hapten, the adjuvant/solvent
used for sensitization and elicitation of the immune re-
sponse, and the housing conditions, which determine the
activation status of memory cells and especially of APCs
(53).
Figure 5. CHSRs in KitW/KitW-v mice depend on mast cell–derived
TNF. KitW/KitW-v mice were reconstituted with mast cells (MC) from ei-
ther congenic WT or TNF2/2 mice, sensitized, and challenged with
TNCB as described in Materials and Methods. The increase of ear thick-
ness was determined 24 h after the challenge (A). The asterisk indicates
significant difference in ear thickness (P , 0.05). (B) Mast cells from
TNF2/2 mice in ear tissue from KitW/KitW-v mice stained with toluidine
blue (arrowheads).1448 Mast Cells Control Neutrophil Recruitment in T Cell–mediated Reactions
Importantly, the deficiency in ear swelling responses and
PMN recruitment in KitW/KitW-v mice can be due to fac-
tors that are independent of mast cells (23, 24). Thus, Kit-
deficient mice have multiple defects in their hematopoietic
system (54), and profound defects in T cell responses or al-
tered migration through vascular walls would be alterna-
tive explanations for defective DTHRs in KitW/KitW-v
mice. This seems not to apply in this system, as hapten-
specific proliferation and IFN-g production were equiva-
lent in T cells of WT and KitW/KitW-v  mice (Fig. 4).
Moreover, elicitation of CHSRs strictly required mast cell
reconstitution at the site of TNCB challenge, whereas mast
cell reconstitution at the site of sensitization with TNCB
did not affect hapten-specific T cell responses, determined
in vitro, or ear swelling responses, or PMN recruitment
(data not shown).
This exclusive role of mast cells in providing the TNF
and, most likely, also the MIP-2 required for the recruit-
ment of PMN during the effector phase of DTHRs was
unexpected, as stromal cells such as fibroblasts, endothelia,
or keratinocytes are other potential sources for these two
mediators. Moreover, others have shown that mast cell–
derived TNF can recruit inflammatory cells by paracrine
induction of chemokines in cells such as fibroblasts (55, 56).
However, immunohistology clearly showed that most of
the MIP-2 protein localized to mast cells and no extractable
MIP-2 was detectable in ear tissues from mast cell–deficient
mice, and mast cells from TNF2/2 mice did not restore
PMN recruitment in KitW/KitW-v mice. As in KitW/KitW-v
mice, the endothelia, fibroblasts, or keratinocytes sur-
rounding the transplanted TNF2/2 mast cells are in princi-
ple capable of producing TNF; this experiment clearly
demonstrated that mast cell–derived TNF cannot be re-
placed by TNF from any other source during TNCB-
induced DTHRs. Moreover, the data underline the need
for a coordinated action of MIP-2 and TNF for the recruit-
ment of PMNs.
The finding that tissue mast cells regulate PMN recruit-
ment in response to infiltrating type 1 T cells through TNF
and MIP-2 may be of general importance for the under-
standing of PMN recruitment during T cell–mediated au-
toimmune diseases. Activated mast cells and increased levels
of MIP-2/IL-8 characterize all T cell–mediated autoim-
mune diseases associated with a predominant PMN accu-
mulation, such as psoriasis (6, 57, 58), rheumatoid- or col-
lagen-induced arthritis (1, 2, 59), Crohn’s disease, and
inflammatory bowel disease (4, 60, 61). Importantly, acti-
vated mast cells and increased levels of TNF are also found
during T cell–mediated autoimmune diseases devoid of
PMNs, such as EAE. In contrast, MIP-2/IL-8 is not in-
duced during EAE and even the mRNA levels for this cy-
tokine remain low (8, 9, 11, 32). One possibility is that
EAE-inducing type 1 T cells express a unique pattern of
surface molecules or cytokines that activate mast cells with-
out inducing MIP-2/IL-8. Alternatively, mast cells of the
central nervous system may have a reduced capacity in pro-
ducing MIP-2/IL-8 in response to infiltrating type 1 T
cells. We favor this second hypothesis, as the type 1 T cells
infiltrating the central nervous system, the skin, the joints,
or the intestinal wall, seem to produce a very similar pat-
tern of cytokines. In contrast, in the different anatomic sites
mast cells represent heterogeneous populations that vary in
many aspects of phenotype, including morphology, his-
tochemistry, mediator content, and response to stimuli of
activation (for a review, see reference 27). In the context of
our findings it is intriguing that Perrin and coworkers
found MIP-2 induction and PMN recruitment during ex-
perimental autoimmune meningitis (62), where mast cells
reside in a loose connective tissue, whereas MIP-2 and
PMN were absent during EAE, as reported previously by
Figure 6. MIP-2 immunoreactivity
in tissue mast cells from TNF2/2
mice. KitW/KitW-v mice were reconsti-
tuted with mast cells from either
TNF2/2 mice (A and B) or congenic
WT mice (C). These animals and, in
addition, TNF2/2 mice (D), were
sensitized and challenged with TNCB.
MIP-2 (A, C, and D) immunoreactiv-
ity was analyzed in fixed cryosections
as described in Materials and Methods.
(B) Analysis of immunoreactivity in
the absence of the primary Ab. Simi-
larly, no staining was found in the cor-
responding controls for C and D.1449 Biedermann et al.
others (8, 9, 11, 32). In line with these experiments, we
found that the capacity of mast cells to produce MIP-2 is
critically influenced by the culture condition (our unpub-
lished data).
It is long recognized that rheumatoid arthritis, Crohn’s
disease, inflammatory bowel disease, and psoriasis are asso-
ciated with type 1 T cells, activated mast cells, MIP-2/
IL-8, and TNF, but the link between these phenomena
was missing (1, 4, 6, 63). Thus, recognizing that mast cells
are capable of regulating the recruitment of PMNs during
DTHRs by producing both TNF and the MIP-2/IL-8 re-
quired for PMN recruitment may be not only relevant for
CHSRs but of general importance for understanding the
mechanisms leading to clinically relevant autoimmune dis-
eases.
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